Clinical Trial Update: A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating upadacitinib for moderate-to-severe Crohn's disease in patients inadequately responding or intolerant to biologics; study completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2022-08-15